Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030407 · ClinicalTrials.gov registry record · Phase 2
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00030407 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 34 participants.
The verdict
NCT00030407, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of celecoxib and docetaxel in treating patients who have non-small cell lung cancer.
Interventions
- DRUG Docetaxel
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2001-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030407
The ClinicalTrials.gov registry entry for NCT00030407 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00030407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030407 about?
NCT00030407 is a clinical study titled "Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the e...
What is the current status of trial NCT00030407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2001-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00030407?
The interventions under investigation include: Docetaxel (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00030407?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.